Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.945
-0.085 (-4.19%)
May 12, 2026, 11:12 AM EDT - Market open
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $331.53 million as of May 12, 2026. Its market cap has increased by 74.57% in one year.
Market Cap
331.53M
Enterprise Value
167.25M
1-Year Change
74.57%
Ranking
Category
Stock Price
$1.95
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $331.53M, an increase of 230.02%. That is a compound annual growth rate of 24.83%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 11, 2026 | 346.02M | 23.40% |
| Dec 31, 2025 | 280.40M | -3.25% |
| Dec 31, 2024 | 289.83M | 3,596.14% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 23, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Puma Biotechnology | 363.42M |
| C4 Therapeutics | 349.27M |
| DiaMedica Therapeutics | 347.55M |
| Neumora Therapeutics | 341.63M |
| Silence Therapeutics | 338.67M |
| Immuneering | 336.43M |
| Surrozen | 336.33M |
| Greenwich LifeSciences | 334.31M |